Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

An Innovative Approach in Nanotechnology-based Delivery System for the Effective Management of Psoriasis

Author(s): Shaheen Parveen, Musheer Ahmed, Sanjula Baboota and Javed Ali*

Volume 28, Issue 13, 2022

Published on: 18 March, 2022

Page: [1082 - 1102] Pages: 21

DOI: 10.2174/1381612828666220201141915

Price: $65

Abstract

Introduction: Psoriasis is an incurable, non-contagious inflammatory autoimmune skin disease characterised by abnormal skin redness and flaky patches on the body surface. It is caused by negative signals produced by the immune system, leading to excessive growth and differentiation of keratinocytes and other inflammatory reactions on the skin. The topical route is primarily preferred in treating skin disorders due to the smaller size of the drug molecule, which allows them to cross the outer layer of the skin, i.e., stratum corneum, and permeate into the deep layer, unlike transdermal and other routes. The conventional topical treatments used in the past, such as coal tar and dithranol, lead to meager patient compliance due to decreased potency and imperfect aesthetic. In contrast, systemic therapy such as methotrexate, cyclosporine, and acitretin produce related side effects. At present, various novel carriers like liposomes, ethosomes, niosomes, nanostructured lipid carriers, etc., have shown promising results in the treatment of psoriasis. Therefore, this review primarily concentrates on the current advancements in novel carriers for various drugs to treat psoriasis topically.

Discussion: The goal of this review is to provide a comprehensive overview of the pathophysiology, epidemiology, types, causes, diagnosis, and topical treatment options for psoriasis, as well as the role of nanotechnology- based delivery systems in psoriasis management.

Keywords: Nanocarriers, nanostructured lipid carriers, solid lipid nanoparticles, psoriasis, emulsions, nanoparticles, liposomes.

« Previous Next »
[1]
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133(2): 377-85.
[http://dx.doi.org/10.1038/jid.2012.339] [PMID: 23014338]
[2]
Pradhan M, Alexander A, Singh M, Singh D, Saraf S. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother 2018; 107: 447-63. Available from: https://www.sciencedirect.com/science/article/pii/S0753332218311351
[3]
Gillard SE, Finlay AY. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. Int J Clin Pract 2005; 59(11): 1260-7.
[http://dx.doi.org/10.1111/j.1368-5031.2005.00680.x] [PMID: 16236077]
[4]
Dubois Declercq S, Pouliot R. Promising new treatments for psoriasis. ScientificWorldJournal 2013; 2013, 980419.
[http://dx.doi.org/10.1155/2013/980419] [PMID: 23935446]
[5]
Mabuchi T, Chang TW, Quinter S, Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci 2012; 65(1): 4-11.
[http://dx.doi.org/10.1016/j.jdermsci.2011.11.007] [PMID: 22177422]
[6]
Dutta S, Chawla S, Kumar S. Psoriasis: a review of existing therapies and recent advances in treatment spontaneous bacterial peritonitis view project pharmacovigilance view project psoriasis: a review of existing therapies and recent advances in treatment. J Ration Pharmacother 2018; 4(1): 2018.
[7]
Pradhan M, Singh D, Singh MR. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Control Release 2013; 170(3): 380-95.
[http://dx.doi.org/10.1016/j.jconrel.2013.05.020] [PMID: 23770117]
[8]
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31(2): 205-12.
[http://dx.doi.org/10.1111/jdv.13854] [PMID: 27573025]
[9]
Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149(10): 1173-9.
[http://dx.doi.org/10.1001/jamadermatol.2013.5015] [PMID: 23925466]
[10]
Traub M, Marshall K. Psoriasis-pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev 2007; 12(4): 319-30.
[PMID: 18069901]
[11]
Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020; 323(19): 1945-60.
[http://dx.doi.org/10.1001/jama.2020.4006] [PMID: 32427307]
[12]
Tom BDM, Chandran V, Farewell VT, Rosen CF, Gladman DD. Validation of the toronto psoriatic arthritis screen version 2 (ToPAS 2). J Rheumatol 2015; 42(5): 841-6.
[http://dx.doi.org/10.3899/jrheum.140857] [PMID: 25834198]
[13]
Nestle FO, Kaplan DHBJ. Mechanisms of disease: psoriasis. New Engl J Med 2009; 361(5): 496-509.
[14]
Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 2015; 33(5)(Suppl. 93): S2-6.
[PMID: 26472336]
[15]
Affandi AM, Khan I. And NNS-D research, 2018 U. Epidemiology and clinical features of adult patients with psoriasis in Malaysia: 10-year review from the Malaysian Psoriasis Registry (2007–2016). Dermatol Res Pract 2018; 1-8.
[http://dx.doi.org/10.1155/2018/4371471]
[16]
Saleem S, Iqubal MK, Garg S, Ali J, Baboota S. Trends in nanotechnology-based delivery systems for dermal targeting of drugs: an enticing approach to offset psoriasis Expert Opinion on Drug Delivery. Taylor & Francis 2020; pp. 817-38.
[http://dx.doi.org/10.1080/17425247.2020.1758665]
[17]
Sewerin P, Brinks R, Schneider M, Haase I, Vordenbäumen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis 2019; 78(2): 286-7.
[http://dx.doi.org/10.1136/annrheumdis-2018-214065] [PMID: 30242033]
[18]
Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol 2012; 22(5): 663-7.
[http://dx.doi.org/10.1684/ejd.2012.1802] [PMID: 22910173]
[19]
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014; 70(3): 512-6.
[http://dx.doi.org/10.1016/j.jaad.2013.11.013] [PMID: 24388724]
[20]
Schleicher SM. Psoriasis: Pathogenesis, Assessment, and Therapeutic Update. Clin Podiatr Med Surg 2016; 33(3): 355-66.
[http://dx.doi.org/10.1016/j.cpm.2016.02.004] [PMID: 27215156]
[21]
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370(9583): 263-71.
[http://dx.doi.org/10.1016/S0140-6736(07)61128-3] [PMID: 17658397]
[22]
Garritsen FM, Kraag DE, de Graaf M. Guttate psoriasis triggered by perianal streptococcal infection. Clin Exp Dermatol 2017; 42(5): 536-8.
[http://dx.doi.org/10.1111/ced.13129] [PMID: 28543851]
[23]
Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol 2018; 32(10): 1645-51.
[http://dx.doi.org/10.1111/jdv.14949] [PMID: 29573491]
[24]
Bardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A. Nail psoriasis: An updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol 2019; 99(6): 516-23.
[http://dx.doi.org/10.2340/00015555-3098] [PMID: 30521057]
[25]
Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol 2017; 44(8): 863-72.
[http://dx.doi.org/10.1111/1346-8138.13806] [PMID: 28349593]
[26]
Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci 2020; 99(1): 2-8.
[http://dx.doi.org/10.1016/j.jdermsci.2020.05.008] [PMID: 32536600]
[27]
Afonina IS, Van Nuffel E, Beyaert R. Immune responses and therapeutic options in psoriasis. Cellular and Molecular Life Sciences. Springer Science and Business Media Deutschland GmbH 2021; pp. 1-19. Available from: https://link.springer.com/article/10.1007/s00018-020-03726-1
[28]
Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev 2014; 13(4-5): 490-5.
[http://dx.doi.org/10.1016/j.autrev.2014.01.008] [PMID: 24434359]
[29]
Kimmel GW, Lebwohl M. Psoriasis: overview and diagnosis 2018. ; 1-16.
[30]
Baadsgaard O, Traulsen J, Roed-Petersen J, Jakobsen H. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatolog Treat 1995; 6(3): 145-50.
[http://dx.doi.org/10.3109/09546639509097171]
[31]
Van de Kerkhof PCM, Green C, Hamberg KJ, et al. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002; 204(3): 214-21.https://www.karger.com/Article/FullText/57884
[http://dx.doi.org/10.1159/000057884] [PMID: 12037450]
[32]
du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975; 111(5): 581-3.https://jamanetwork.com/journals/jamadermatology/fullarticle/534953
[http://dx.doi.org/10.1001/archderm.1975.01630170039002] [PMID: 1130802]
[33]
Fereig SA, El-Zaafarany GM, Arafa MG, Abdel-Mottaleb MMA. Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis. Drug Deliv 2020; 27(1): 662-80.
[http://dx.doi.org/10.1080/10717544.2020.1754527] [PMID: 32393082]
[34]
Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol 2012; 2012(iv), 561018.
[http://dx.doi.org/10.1155/2012/561018] [PMID: 23213332]
[35]
Zeichner JA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol 2010; 3(9): 37-40.
[PMID: 20877524]
[36]
Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol 1992; 27(6 Pt 1): 1001-8.
[http://dx.doi.org/10.1016/0190-9622(92)70302-V] [PMID: 1479078]
[37]
Kemeny L, Ruzicka T, Falco-braun O. Dithranol:a review of mechanism of action in the treatment of psoriasis vulgaris 1990. Off J Ski Pharmacol 1990; 3(1): 1-20.. Available from: http://www.ghbook.ir/index.php?name=
[38]
Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999; 38(1): 16-24.
[http://dx.doi.org/10.1046/j.1365-4362.1999.00500.x] [PMID: 10065604]
[39]
Marks R. The role of tazarotene in the treatment of psoriasis. Br J Dermatol 1999; 140(54)(Suppl. 54): 24-8.
[http://dx.doi.org/10.1046/j.1365-2133.1999.140S54024.x] [PMID: 10731131]
[40]
Action M, Sehgal VN, Srivastava G, Dogra S. Tacrolimus in dermatology:pharmacokinetics mechanism of action,drug interaction,dosages,ans side effects:1. Skinmed 2007; 7(1): 27-30.
[41]
Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis Expert Opinion on Drug Delivery. Taylor and Francis Ltd 2016; pp. 1461-73.
[http://dx.doi.org/10.1080/17425247.2016.1188801]
[42]
Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol 2010; 76(6): 612-21.
[http://dx.doi.org/10.4103/0378-6323.72451] [PMID: 21079304]
[43]
Gupta S, Bansal R, Gupta S, Jindal N, Jindal A. Nanocarriers and nanoparticles for skin care and dermatological treatments. Indian Dermatol Online J 2013; 4(4): 267-72.
[http://dx.doi.org/10.4103/2229-5178.120635] [PMID: 24350003]
[44]
Deng Y, Zhang X, Shen H, et al. Application of the nano-drug delivery system in treatment of cardiovascular diseases. Front Bioeng Biotechnol 2020; 7(January): 489.
[http://dx.doi.org/10.3389/fbioe.2019.00489] [PMID: 32083068]
[45]
Vincent N, Ramya DD, Vedha HB. Progress in psoriasis therapy via novel drug delivery systems. Dermatol Rep 2014; 6(1): 5451.
[http://dx.doi.org/10.4081/dr.2014.5451] [PMID: 25386329]
[46]
Murphy EC, Schaffter SW, Friedman AJ. Nanotechnology for Psoriasis Therapy. Vol. 8, Current Dermatology Reports. Current Medicine Group LLC 2019; 1: 14-25.
[47]
Baroli B, Ennas MG, Loffredo F, Isola M, Pinna R, López-Quintela MA. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol 2007; 127(7): 1701-12.
[http://dx.doi.org/10.1038/sj.jid.5700733] [PMID: 17380118]
[48]
Palmer BC, DeLouise LA. Nanoparticle-enabled transdermal drug delivery systems for enhanced dose control and tissue targeting. Molecules 2016; 21(12): 1719.
[http://dx.doi.org/10.3390/molecules21121719] [PMID: 27983701]
[49]
Rahman M, Beg S, Ahmad MZ, et al. Omega-3 fatty acids as pharmacotherapeutics in psoriasis: current status and scope of nanomedicine in its effective delivery. Curr Drug Targets 2013; 14(6): 708-22.
[http://dx.doi.org/10.2174/1389450111314060011] [PMID: 23531113]
[50]
Erdmann VA, Barciszewski J. DNA and RNA nanobiotechnologies in medicine: Diagnosis and treatment of diseases. DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases. 2013; pp. 1-460..
[51]
Joshi D, Garg T, Goyal AK, Rath G. Development and characterization of novel medicated nanofibers against periodontitis. Curr Drug Deliv 2015; 12(5): 564-77.
[http://dx.doi.org/10.2174/1567201812666141205131331] [PMID: 25488417]
[52]
Kalia V, Garg T, Rath G, Goyal AK. Development and evaluation of a sublingual film of the antiemetic granisetron hydrochloride. Artif Cells Nanomed Biotechnol 2016; 44(3): 842-6.
[PMID: 25435408]
[53]
Pandey K. Nimisha. An overview on promising nanotechnological approaches for the treatment of psoriasis. Recent Pat Nanotechnol 2020; 14(2): 102-18.
[http://dx.doi.org/10.2174/1872210514666200204124130] [PMID: 32013854]
[54]
Damiani G, Pacifico A, Linder DM, et al. Nanodermatology-based solutions for psoriasis: State-of-the art and future prospects. Dermatol Ther 2019; 32(6), e13113.
[http://dx.doi.org/10.1111/dth.13113] [PMID: 31600849]
[55]
Ahmed TA. Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett-Burman design and characterization. J Liposome Res 2015; 25(1): 1-10.
[http://dx.doi.org/10.3109/08982104.2014.950276] [PMID: 25148294]
[56]
Rahman M, Akhter S, Ahmad J. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin Drug Deliv 2015; 12(4): 635-52.
[http://dx.doi.org/10.1517/17425247.2015.982088] [PMID: 25439967]
[57]
Prajapati BG, Patel NK, Panchal MM, Patel RP. Topical liposomes in drug delivery: A Review. Ijprt 2012; 4(1): 39-44.
[58]
Jindal S, Awasthi R, Singhare D, Kulkarni GT. Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis. Med Hypotheses 2020; 142(March), 109838.
[http://dx.doi.org/10.1016/j.mehy.2020.109838] [PMID: 32442677]
[59]
Wadhwa S, Singh B, Sharma G, Raza K, Katare OP. Liposomal fusidic acid as a potential delivery system: a new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv 2016; 23(4): 1204-13.
[http://dx.doi.org/10.3109/10717544.2015.1110845] [PMID: 26592918]
[60]
Raza K, Singh B, Lohan S, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm 2013; 456(1): 65-72.https://pubmed.ncbi.nlm.nih.gov/23973754/
[http://dx.doi.org/10.1016/j.ijpharm.2013.08.019] [PMID: 23973754]
[61]
Walunj M, Doppalapudi S, Bulbake U, Khan W. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J Liposome Res 2020; 30(1): 68-79.
[http://dx.doi.org/10.1080/08982104.2019.1593449] [PMID: 30897993]
[62]
Desmet E, Bracke S, Forier K, et al. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis. Int J Pharm 2016; 500(1-2): 268-74.
[http://dx.doi.org/10.1016/j.ijpharm.2016.01.042] [PMID: 26806466]
[63]
Bahramizadeh M, Bahramizadeh M, Kiafar B, et al. Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model. Int J Pharm 2019; 569, 118623.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118623] [PMID: 31419462]
[64]
Knudsen NØ, Rønholt S, Salte RD, et al. Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm 2012; 81(3): 532-9.
[http://dx.doi.org/10.1016/j.ejpb.2012.04.005] [PMID: 22538098]
[65]
Yadav K, Singh D, Singh MR, Pradhan M. Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis. Med Hypotheses 2020; 145, 110322.
[http://dx.doi.org/10.1016/j.mehy.2020.110322] [PMID: 33086162]
[66]
Rakesh R, Anoop KR. Ethosomes for transdermal and topical drug delivery. Int J Pharm Pharm Sci 2012; 4.
[67]
Sharma P, Verma S, Misri P. Global need for novel herbal drug formulations. Int J Pharmacogn Phytochem Res 2016; 8(9): 1535-44.
[68]
Zhang Y, Xia Q, Li Y, et al. CD44 assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: A new strategy for clustering drug in inflammatory skin. Theranostics 2019; 9(1): 48-64.
[http://dx.doi.org/10.7150/thno.29715]
[69]
Zhang YT, Shen LN, Zhao JH, Feng NP. Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis. Int J Nanomedicine 2014; 9(1): 669-78.
[http://dx.doi.org/10.2147/IJN.S57314] [PMID: 24489470]
[70]
Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007; 123(2): 148-54.
[http://dx.doi.org/10.1016/j.jconrel.2007.08.005] [PMID: 17884226]
[71]
Akhilesh C, Geeta A. Manchandra Satish. NA. Development of Topical Gel of Methotrexate Incorporated Ethosomes. Ingenta Connect. Pharm Nanotechnol 2019; 362-74.. https://www.ingentaconnect.com/content/ben/pnt/2019/00000007/00000005/art00005
[72]
Sharma D, Ali AAE, Aate JR. Niosomes as novel drug delivery system: review article. Pharmatutor 2018; 6(3): 58.
[http://dx.doi.org/10.29161/PT.v6.i3.2018.58]
[73]
Meng S, Sun L, Wang L, et al. Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity. Colloids Surf B Biointerfaces 2019; 182, 110352.
[http://dx.doi.org/10.1016/j.colsurfb.2019.110352] [PMID: 31306831]
[74]
Abdelbary AA, AbouGhaly MHH. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm 2015; 485(1-2): 235-43.
[http://dx.doi.org/10.1016/j.ijpharm.2015.03.020] [PMID: 25773359]
[75]
Almaghrabi MA. Preparation And Characterization Of Acitretin-Loaded Niosomes For Psoriasis Treatment 2017. Available from: https://egrove.olemiss.edu/etd/727
[76]
Marianecci C, Rinaldi F, Di Marzio L, et al. Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models. Int J Nanomedicine 2014; 9: 635-51.
[http://dx.doi.org/10.2147/IJN.S55066] [PMID: 24493924]
[77]
Gill B, Singh J, Sharma V, Hari Kumar S. Emulsomes: An emerging vesicular drug delivery system. Vol. 6. Asian J Pharm 2012; 87-94.
[http://dx.doi.org/10.4103/0973-8398.102930]
[78]
Journal AI, Gupta R, Gupta M, Mangal S, Agrawal U. Artificial Cells, Nanomedicine, and Biotechnology Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy. 2014. Available from:. https://www.tandfonline.com/action/journalInformation?journalCode=ianb20
[79]
Raza K, Katare OP, Setia A, Bhatia A, Singh B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul 2013; 30(3): 225-36.
[http://dx.doi.org/10.3109/02652048.2012.717115] [PMID: 23088318]
[80]
P.R. K; Yadav J.D., K.A. V, Gandhi P P. Transferosomes: An emerging tool for transdermal drug delivery. Int J Pharm Sci Res 2011; 2(4): 735-41.[Available from. http://www.ijpsr.com/V2I4/3ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=368483038
[81]
Lei W, Yu C, Lin H, Zhou X. Development of tacrolimus-loaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo. Asian J Pharm Sci 2013; 8(6): 336-45.
[http://dx.doi.org/10.1016/j.ajps.2013.09.005]
[82]
Abdallah MH, Lila ASA, Anwer MK, Khafagy E-S, Mohammad , M.S.Soliman . Formulation, development and evaluation of ibuprofen loaded nano-transferosomal gel for the treatment of psoriasis. J Pharm Res Int 2019; 31(6): 1-8.
[http://dx.doi.org/10.9734/jpri/2019/v31i630356]
[83]
El Gizaway S, Fadel M, Mourad B, Elnaby FEA. Betamethasone dipropionate gel for treatment of localized plaque Psoriasis. Int J Pharm Pharm Sci 2017; 9(8): 173.
[http://dx.doi.org/10.22159/ijpps.2017v9i8.18571]
[84]
Gurpret K, Singh SK. Review of nanoemulsion formulation and characterization techniques. Indian J Pharm Sci 2018; 80(5): 781-9.https://www.ijpsonline.com/articles/review-of-nanoemulsion-formulation-and-characterization-techniques-3530.html
[http://dx.doi.org/10.4172/pharmaceutical-sciences.1000422]
[85]
Kaur A, Katiyar SS, Kushwah V, Jain S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine 2017; 13(4): 1473-82.
[http://dx.doi.org/10.1016/j.nano.2017.02.009] [PMID: 28259803]
[86]
Rajitha P, Shammika P, Aiswarya S, Gopikrishnan A, Rangasamy JMS Chaulmoogra. oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J Drug Deliv Sci Technol 2019; 49.
[http://dx.doi.org/10.1016/j.jddst.2018.12.020]
[87]
Musa SH, Salim N, Shamsudin N, Basri M, Hamid RFM. Development of cyclosporine-loaded nanoemulsion for topical treatment of psoriasis . Int J Res Pharm Sci 2019; 10(SPL1). Available from: https://pharmascope.org/ijrps/article/view/1676
[88]
Sahu S, Katiyar SS, Kushwah V, Jain S. Active natural oil-based nanoemulsion containing tacrolimus for synergistic antipsoriatic efficacy. Nanomedicine (Lond) 2018; 13(16): 1985-98.
[http://dx.doi.org/10.2217/nnm-2018-0135] [PMID: 30188761]
[89]
Algahtani MS, Ahmad MZ, Ahmad J. Nanoemulsion loaded polymeric hydrogel for topical delivery of curcumin in psoriasis. J Drug Deliv Sci Technol 2020; 59, 101847.
[http://dx.doi.org/10.1016/j.jddst.2020.101847]
[90]
Ekambaram P, Sathali AH, Priyanka K. Solid lipid nanoparticles- A review. Int J Appl Pharm 2012; 2(2): 80-102.
[91]
Misra AR. Methotrexate-Loaded Solid Lipid Nanoparticles for Topical Treatment of Psoriasis: Formulation & Clinical Implications. 2004; 1-11.. Available from: https://www.academia.edu/ 7853173/Methotrexate_Loaded_Solid_Lipid_Nanoparticles_for_Topical_Treatment_of_Psoriasis_Formulation_and_Clinical_Implications
[92]
Trombino S, Russo R, Mellace S, Varano GP, et al. Solid lipid nanoparticles made of trehalose monooleate for cyclosporin-A topic release. J Drug Deliv Sci Technol 2019; 49: 563-9.
[http://dx.doi.org/10.1016/j.jddst.2018.12.026]
[93]
Bikkad ML, Nathani AH, Mandlik SK, Shrotriya SN, Ranpise NS. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. J Liposome Res 2014; 24(2): 113-23.https://pubmed.ncbi.nlm.nih.gov/24131382/
[http://dx.doi.org/10.3109/08982104.2013.843192] [PMID: 24131382]
[94]
Madan JR, Khude PA, Dua K. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int J Pharm Investig 2014; 4(2): 60-4.
[http://dx.doi.org/10.4103/2230-973X.133047] [PMID: 25006550]
[95]
Sonawane R, Harde H, Katariya M, Agrawal S, Jain S. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin Drug Deliv 2014; 11(12): 1833-47.
[http://dx.doi.org/10.1517/17425247.2014.938634] [PMID: 25078031]
[96]
A HAmSa. (PDF) Lipid nanoparticles: A modern formulation approach in topical drug delivery systems. J Adv Drug Deliv 2014; 30-7. Available from: . https://www.researchgate.net/publication/264784523_Lipid_nanoparticles_A_modern_formulation_approach_in_topical_drug_delivery_systems
[97]
Avasatthi V, Pawar H, Dora CP, Bansod P, Gill MS, Suresh S. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation. Pharm Dev Technol 2016; 21(5): 554-62.
[http://dx.doi.org/10.3109/10837450.2015.1026605] [PMID: 26024238]
[98]
Sharma A, Upadhyay DK, Sarma GS, Kaur N, Das Gupta G, Narang RK, et al. Squalene integrated NLC based gel of tamoxifen citrate for efficient treatment of psoriasis: A preclinical investigation: Tamoxifen citrate loaded NLC based gel for psoriasis. J Drug Deliv Sci Technol 2020; 56, 101568.
[http://dx.doi.org/10.1016/j.jddst.2020.101568]
[99]
Pradhan M, Alexander A, Singh MR, Singh D, Saraf S, Saraf S, et al. Statistically optimized calcipotriol fused nanostructured lipid carriers for effectual topical treatment of psoriasis. J Drug Deliv Sci Technol 2020., 102168.
[http://dx.doi.org/10.1016/j.jddst.2020.102168]
[100]
Vishal Gupta N, Kowshik K, Sehgal N. Development of nano structured lipid carrier based hydrogel for the treatment of psoriasis. Int J Res Pharm Sci 2019; 10(3): 1711-9.
[http://dx.doi.org/10.26452/ijrps.v10i3.1360]
[101]
Iriventi P, Gupta Nv. Topical delivery of curcumin and caffeine mixture-loaded nanostructured lipid carriers for effective treatment of psoriasis. Pharmacogn Mag 2020; 16(68): 206.
[http://dx.doi.org/10.4103/pm.pm_260_19]
[102]
Sathe P, Saka R, Kommineni N, Raza K, Khan W. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model. Drug Dev Ind Pharm 2019; 45(5): 826-38.
[http://dx.doi.org/10.1080/03639045.2019.1576722] [PMID: 30764674]
[103]
Madan JR, Khobaragade S, Dua K, Awasthi R. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast. Dermatol Ther 2020; 33(3), e13370.
[http://dx.doi.org/10.1111/dth.13370] [PMID: 32250507]
[104]
Agrawal YO, Mahajan UB, Mahajan HS, Ojha S. Methotrexate-loaded nanostructured lipid carrier gel alleviates imiquimod-induced psoriasis by moderating inflammation: formulation, optimization, characterization, in-vitro and in-vivo studies. Int J Nanomed 2020; 15: 4763-78.
[http://dx.doi.org/10.2147/IJN.S247007] [PMID: 32753865]
[105]
Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical deliveryInt J Nanomed 2010; 5(1): 117-28.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841490/
[PMID: 20309398]
[106]
Nam SH, Ji XY, Park JS. Investigation of tacrolimus loaded nanostructured lipid carriers for topical drug delivery. Bull Korean Chem Soc 2011; 32(3): 956-60.
[http://dx.doi.org/10.5012/bkcs.2011.32.3.956]
[107]
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Delivery Sci Technol 2019; 51: 255-67.
[108]
Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des 2006; 12(36): 4669-84.
[http://dx.doi.org/10.2174/138161206779026245] [PMID: 17168771]
[109]
Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999; 48(2): 101-11.
[http://dx.doi.org/10.1016/S0939-6411(99)00039-9] [PMID: 10469928]
[110]
Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm 2014; 11(9): 2989-3001.
[http://dx.doi.org/10.1021/mp400639e] [PMID: 25057896]
[111]
Khurana B, Arora D, Narang RK. QbD based exploration of resveratrol loaded polymeric micelles based carbomer gel for topical treatment of plaque psoriasis: In vitro, ex vivo and in vivo studies. J Drug Deliv Sci Technol 2020; 59, 101901.
[http://dx.doi.org/10.1016/j.jddst.2020.101901]
[112]
Guterres SS, Alves MP, Pohlmann AR. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007; 2: 147-57.
[http://dx.doi.org/10.1177/117739280700200002] [PMID: 21901071]
[113]
Ramezanli T, Kilfoyle BE, Zhang Z, Michniak-Kohn BB. Polymeric nanospheres for topical delivery of vitamin D3. Int J Pharm 2017; 516(1-2): 196-203.
[http://dx.doi.org/10.1016/j.ijpharm.2016.10.072] [PMID: 27810351]
[114]
Batheja P, Sheihet L, Kohn J, Singer AJ, Michniak-Kohn B. Topical drug delivery by a polymeric nanosphere gel: Formulation optimization and in vitro and in vivo skin distribution studies. J Control Release 2011; 149(2): 159-67.
[http://dx.doi.org/10.1016/j.jconrel.2010.10.005] [PMID: 20950659]
[115]
Erdoğar N, Akkın S, Bilensoy E. Nanocapsules for drug delivery: an updated review of the last decade. Recent Pat Drug Deliv Formul 2018; 12(4): 252-66.
[http://dx.doi.org/10.2174/1872211313666190123153711] [PMID: 30674269]
[116]
Savian AL, Rodrigues D, Weber J, et al. Dithranol-loaded lipid-core nanocapsules improve the photostability and reduce the in vitro irritation potential of this drug. Mater Sci Eng C 2015; 46: 69-76.
[http://dx.doi.org/10.1016/j.msec.2014.10.011] [PMID: 25491961]
[117]
Beber TC, de Andrade DF, Chaves Pdos S, Pohlmann AR, Guterres SS, Beck RC. Cationic polymeric nanocapsules as a strategy to target dexamethasone to viable epidermis: Skin penetration and permeation studies. J Nanosci Nanotechnol 2016; 16(2): 1331-8.
[http://dx.doi.org/10.1166/jnn.2016.11670] [PMID: 27433583]
[118]
Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, et al. Dendrimers: Synthesis, applications, and properties. Vol. 9, Nanoscale Research Letters. Springer New York 2014; LLC: 1-10.
[119]
Chauhan AS. Dendrimers for drug delivery. Molecules 2018; 23(4), E938.
[http://dx.doi.org/10.3390/molecules23040938] [PMID: 29670005]
[120]
Tripathi PK, Gorain B, Choudhury H, Srivastava A, Kesharwani P. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon 2019; 5(3), e01343.
[http://dx.doi.org/10.1016/j.heliyon.2019.e01343] [PMID: 30957038]
[121]
Pandi P, Jain A, Kommineni N, Ionov M, Bryszewska M, Khan W. Dendrimer as a new potential carrier for topical delivery of siRNA: A comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA. Int J Pharm 2018; 550(1-2): 240-50.
[http://dx.doi.org/10.1016/j.ijpharm.2018.08.024] [PMID: 30165098]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy